phrykt

Hepion Pharmaceuticals, Inc. (HEPA): who owns it and who trades it

As of Oct 30, 2026, HEPA insiders reported 6 purchases worth $785K in the last 12 months. The largest buyer was Vincent S LoPriore (Chair), with $600K.

Latest filing Oct 30, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Insider trades

In the last 12 months, HEPA insiders reported $785K of open-market purchases and $0 of sales.

Purchases, 12 months
$785K
6 trades, 5 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Sep 29, 2026
Filed Oct 2, 2026

Purchases and sales by month

$525K$525KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Sep 29, 2026Danina FisherDirectorPurchase200,000$0.05$10KForm 4
Aug 3, 2026Gary S. Stetz IIDirectorPurchase500,000$0.05$25KForm 4
Aug 3, 2026Gary S. StetzCEOPurchase2.00M$0.05$100KForm 4
Aug 3, 2026Vincent S LoPrioreChairPurchase8.00M$0.05$400KForm 4
Apr 21, 2026Michael J. PurcellDirectorPurchase1.25M$0.04$50KForm 4
Apr 21, 2026Vincent S LoPrioreChairPurchase5.00M$0.04$200KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Vincent S LoPrioreExecutive Chairman, Director, 10% owner$600K–Aug 3, 2026
Gary S. StetzInterim CEO, Director$100K–Aug 3, 2026
Michael J. PurcellDirector$50K–Apr 21, 2026
Gary S. Stetz IIDirector$25K–Aug 3, 2026
Danina FisherDirector$10K–Sep 29, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

HEPA short interest

Low short interest. Less than 0.1% of HEPA shares are sold short. Over the last 12 reports the number of shares short went down 100%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 15 HEPA shares were sold short, 0.0% of the shares outstanding, down 99.6% from the report before. At the average daily volume of 57,766 shares, buying them all back would take about 1.0 trading days (days to cover).

Shares short, % of all shares

0.00%May 15Oct 300.16%

Days to cover

1.0May 15Oct 301.1

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 2026150.00%-100%57,7661.0
Oct 15, 20263,8540.00%-74%41,3991.0
Sep 30, 202614,8620.02%+209%108,9511.0
Sep 15, 20264,8160.01%+38%57,0801.0
Aug 31, 20263,4800.00%-82%69,3391.0
Aug 14, 202619,4480.02%+1226%81,6281.0
Jul 31, 20261,4670.01%-84%107,5551.0
Jul 15, 20269,0270.08%-11%22,1591.0
Jun 30, 202610,1480.09%+63325%13,0891.0
Jun 15, 2026160.00%No change13,0091.0
May 29, 2026160.00%-100%59,6921.0
May 15, 202616,5300.14%-30%83,8271.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Hepion Pharmaceuticals company events

Hepion Pharmaceuticals filed 14 reports on Form 8-K in the last 12 months, 7 of them about an important change (leadership, auditor). The latest was on Oct 9, 2026.

  1. Oct 9, 2026LeadershipThe board of directors of the Company appointed Gary Stetz, the Company’s former Interim Chief Executive Officer, to serve as the Company’s Chief Financial Officer, and Sireesh Appajosyula, PharmD, the former Chief Executive Officer of Gravitas Life Sciences, LLC, to serve as the Company’s Chief… Filing
  2. Oct 2, 2026RulesChanged its bylaws or articles. Filing
  3. Sep 28, 2026AuditorChanges in Registrant’s Certifying Accountant. Filing
  4. Sep 8, 2026AgreementHepion Pharmaceuticals, Inc. entered into a convertible note purchase agreement with Gravitas Capital LP pursuant to which the Company issued a $500,000 secured convertible note to Gravitas along with a warrant to purchase 12,500,000 shares of Common Stock of the Company. Filing
  5. Aug 27, 2026AgreementHepion Pharmaceuticals, Inc. entered into securities purchase agreements with certain accredited investors pursuant to which the Company agreed to sell and issue to the Investors in a private placement offering, an aggregate offering of 8,000,000 shares of common stock, par value $0.0001 per share… Filing
  6. Aug 20, 2026LeadershipThe Board of Directors of Hepion Pharmaceuticals, Inc. approved the appointment of James Liddy as a director of the Company, effective immediately. Filing
  7. Aug 4, 2026AgreementHepion Pharmaceuticals, Inc. entered into securities purchase agreements with certain accredited investors pursuant to which the Company agreed to sell and issue to the Investors in a private placement offering, an aggregate offering of 61,100,000 shares of common stock, par value $0.0001 per share… Filing
  8. Jul 2, 2026LeadershipThe Board of Directors of Hepion Pharmaceuticals, Inc. approved the appointment of Danina Fisher and Gary S. Stetz, II as directors of the Company, effective immediately. Filing
  9. Jun 17, 2026VoteReported shareholder vote results. Filing
  10. Apr 22, 2026AgreementHepion Pharmaceuticals, Inc. entered into securities purchase agreements with certain accredited investors pursuant to which the Company agreed to sell and issue to the Investors in a private placement offering, an aggregate offering of 17,500,000 shares of common stock, par value $0.0001 per share… Filing
  11. Apr 14, 2026LeadershipThe information set forth above under Item 1.01 is incorporated herein by reference. Filing
  12. Mar 18, 2026LeadershipDr. Kaouthar Lbiati, the Chief Executive Officer of Hepion Pharmaceuticals, Inc. informed the Board of Directors of the Company that she was resigning as Chief Executive Officer for personal reasons, effective immediately. Filing
  13. Mar 3, 2026AgreementHepion Pharmaceuticals, Inc., a Delaware corporation, entered into an intellectual property license agreement with Cirna Diagnostics, LLC pursuant to which the Company licensed certain liver disease diagnostic assets from Cirna. Filing
  14. Jan 15, 2026LeadershipThe Board of Directors of Hepion Pharmaceuticals, Inc., a Delaware corporation, approved the employment agreement of Dr. Kaouthar Lbiati as Chief Executive Officer, effective as of January 8, 2026. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Hepion Pharmaceuticals financials

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named HEPA in the last 120 days.

FiledHolderFormStake
Oct 26, 2026Gravitas Collective Corp.13D19.9%
Oct 26, 2026Gravitas Collective Corp.13D19.9%
Oct 21, 2026Kenneth Rickel13G/A7.2%
Oct 21, 2026Kenneth Rickel13G/A7.2%

Questions about Hepion Pharmaceuticals, Inc. (HEPA) stock

Are HEPA insiders buying or selling?

In the last 12 months, HEPA insiders reported 6 open-market purchases worth $785K and no sales. The latest trade was on Sep 29, 2026. See every trade.

What is the short interest in HEPA?

As of Oct 30, 2026, 15 HEPA shares were sold short, 0.0% of the shares outstanding, down 99.6% from the report before. At the average daily volume of 57,766 shares, buying them all back would take about 1.0 trading days (days to cover). See the history.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.